Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ferran

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Poultry Science|August 29, 2024
Pharmacokinetic modeling of sulfamethoxazole-trimethoprim and sulfadiazine-trimethoprim combinations in broilersMarine Boulanger, Jean-François Taillandier, Jérôme Henri, et al.
BMC Veterinary Research|June 5, 2026
Comparative pharmacokinetics of trimethoprim-sulfadiazine and trimethoprim-sulfamethoxazole in dogsCarl Ekstrand, Minerva Löwgren, Malin Erkas, et al.
Computer Methods in Biomechanics and Biomedical Engineering|December 15, 2010
Motion analysis of the glenohumeral joint during activities of daily livingB Lovern, L A Stroud, N A Ferran, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 7, 2023
Biased computation of probability of target attainment for antimicrobial drugsPierre-Louis Toutain, Peggy Gandia, Ludovic Pelligand, et al.
Clinical Pharmacokinetics|June 13, 2019
Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|June 13, 2019
Author's Reply to Trechot: "Comment on Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|June 5, 2019
Authors' Reply to Coste et al.: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|August 28, 2019
Authors' Reply to Lechat et al.: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Frontiers in Pharmacology|December 3, 2024
Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against <i>Rhodococcus equi</i> at concentrations achievable in foalsAnne-Sophie Huguet, Ophélie Gourbeyre, Agathe Bernand, et al.
Clinical Pharmacokinetics|August 22, 2019
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Poultry Science|August 29, 2024
Pharmacokinetic modeling of sulfamethoxazole-trimethoprim and sulfadiazine-trimethoprim combinations in broilersMarine Boulanger, Jean-François Taillandier, Jérôme Henri, et al.
BMC Veterinary Research|June 5, 2026
Comparative pharmacokinetics of trimethoprim-sulfadiazine and trimethoprim-sulfamethoxazole in dogsCarl Ekstrand, Minerva Löwgren, Malin Erkas, et al.
Computer Methods in Biomechanics and Biomedical Engineering|December 15, 2010
Motion analysis of the glenohumeral joint during activities of daily livingB Lovern, L A Stroud, N A Ferran, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 7, 2023
Biased computation of probability of target attainment for antimicrobial drugsPierre-Louis Toutain, Peggy Gandia, Ludovic Pelligand, et al.
Clinical Pharmacokinetics|June 13, 2019
Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|June 13, 2019
Author's Reply to Trechot: "Comment on Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|June 5, 2019
Authors' Reply to Coste et al.: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Clinical Pharmacokinetics|August 28, 2019
Authors' Reply to Lechat et al.: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Frontiers in Pharmacology|December 3, 2024
Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against <i>Rhodococcus equi</i> at concentrations achievable in foalsAnne-Sophie Huguet, Ophélie Gourbeyre, Agathe Bernand, et al.
Clinical Pharmacokinetics|August 22, 2019
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, et al.
Pageof 9